Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer

Clinical Lung Cancer

Volumn 11, Issue 5, 2010, Pages 328-334

  Grimminger, Peter ^a,c   Schneider, Paul ^b   Metzger, Ralf ^a   Vallböhmer, Daniel ^a   Hölscher, Arnulf ^a   Danenberg, Peter ^c   Brabender, Jan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b University Cinic Zürich   (Switzerland)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

5 Fluorouracil; Adenocarcinoma; Prognosis; Squamous cell carcinoma

Indexed keywords

BETA ACTIN; BIOLOGICAL MARKER; DIHYDROPYRIMIDINE DEHYDROGENASE; MESSENGER RNA; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; LUNG; LUNG NEOPLASMS; MALE; PROGNOSIS; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 77957034619     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.041     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-249
2. Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute. Bethesda, MD, 2008.
3. Brabender J, Vallbohmer D, Grimminger P, et al. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J Gastrointest Surg 2008; 12:1815-1821
4. Kim YC, Park KO, Kern JA, et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998; 22:181-190
5. Kwiatkowski DJ, Harpole DH, Jr, Godleski J, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998; 16:2468-2477
6. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-2291
7. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006; 19:425-432
8. Miao XP, Li JS, Li HY, et al. Expression of ornithine decarboxylase in precancerous and cancerous gastric lesions. World J Gastroenterol 2007; 13:2867-2871
9. Strauss GM, Kwiatkowski DJ, Harpole DH, et al. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 1995; 13:1265-1279
10. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7:1850-1855
11. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002; 235:440-443 (Pubitemid 34183896)
12. Grimminger P, Ling FC, Neiss S, et al. The role of the homeobox genes BFT and CDX2 in the pathogenesis of non-small cell lung cancer. Anticancer Res 2009; 29:1281-1286
13. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179:663-666
14. Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998; 334:1-8.
15. Lu ZH, Zhang R, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992; 267:17102-17109
16. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45:5405-5412
17. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47:2203-2206
18. Farrugia DC, Ford HE, Cunningham D, et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 2003; 9:792-801.
19. Huang CL, Yokomise H, Kobayashi S, et al. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 2000; 17:47-54.
20. Kakimoto M, Uetake H, Osanai T, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett 2005; 223:103-111
21. Kuramochi H, Hayashi K, Uchida K, et al. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemother Pharmacol 2008; 63:85-89
22. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14:176-182
23. Miyoshi Y, Uemura H, Ishiguro H, et al. Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis 2005; 8:260-265
24. Schneider S, Uchida K, Brabender J, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005; 200:336-344
25. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-4304
26. Uchida K, Danenberg PV, Danenberg KD, et al. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008; 8:386.
27. Vallbohmer D, Yang DY, Kuramochi H, et al. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol 2007; 31:413-418
28. Metzger R, Danenberg K, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4:2371-2376
29. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327
30. Han JY, Hong EK, Lee SY, et al. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. J Clin Pathol 2005; 58:650-654
31. Saif MW, Hashmi S, Bell D, et al. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival. Expert Opin Drug Saf 2009; 8:507-514
32. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159
33. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4:135-142
34. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6:995-1001.
35. Pike MC. Asymptomatically efficient rank invariant procedures. J R Stat Soc [Ser A] 1972; 135:201-203
36. Miller R, Siegmund D. Maximally selected chi-square statistics. Biometrics 1982; 38:1011-1016
37. Halpern J. Maximally selected chi-square statistics for small samples. Biometrics 1982; 38:1017-1023
38. Nakano J, Huang C, Liu D, et al. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006; 95:607-615
39. Shintani Y, Ohta M, Hirabayashi H, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer 2004; 45:189-196
40. Zheng Z, Li X, Schell MJ, et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008; 112:2765-2773
41. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-1412
42. Miyoshi T, Kondo K, Fujino H, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity. Anticancer Res 2005; 25:923-930
43. Soong R, Shah N, Salto-Tellez M, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008; 19:915-919
44. Chujo M, Miura T, Kawano Y, et al. Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues. Oncol Rep 2006; 16:777-780
45. Yano T, Koga T, Ninomiya S, et al. Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues. Int J Clin Oncol 2002; 7:361-364
46. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107:1589-1596
47. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58:685-690
48. Nishimura G, Terada I, Kobayashi T, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002; 9:479-482
49. Nishida M, Hino A, Mori K, et al. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996; 19:1407-1411
50. Boskos CS, Liacos C, Korkolis D, et al. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. J Surg Oncol 2009; [Epub ahead of print].
51. Saito K, Khan K, Yu SZ, et al. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer. Laryngoscope 2009; 119:82-88